Eversept Partners LP Lowers Stock Holdings in Bruker Corporation $BRKR

Eversept Partners LP reduced its holdings in Bruker Corporation (NASDAQ:BRKR) by 85.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 117,013 shares of the medical research company’s stock after selling 666,776 shares during the period. Eversept Partners LP’s holdings in Bruker were worth $4,227,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in BRKR. Allworth Financial LP raised its stake in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after buying an additional 257 shares during the period. Federated Hermes Inc. grew its stake in Bruker by 6.7% in the 4th quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock valued at $284,000 after acquiring an additional 380 shares during the period. Parallel Advisors LLC increased its holdings in Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after acquiring an additional 479 shares in the last quarter. State of Michigan Retirement System raised its position in Bruker by 1.9% during the first quarter. State of Michigan Retirement System now owns 26,693 shares of the medical research company’s stock worth $964,000 after acquiring an additional 500 shares during the period. Finally, CWM LLC raised its position in Bruker by 49.8% during the fourth quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock worth $77,000 after acquiring an additional 542 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on BRKR shares. Guggenheim lifted their target price on shares of Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Leerink Partners raised their price target on shares of Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Barclays lifted their price objective on Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Finally, UBS Group set a $60.00 price objective on Bruker in a research note on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Bruker currently has an average rating of “Hold” and a consensus target price of $56.79.

Bruker Trading Down 0.7%

Shares of BRKR opened at $60.05 on Tuesday. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $64.54. The stock has a market cap of $9.14 billion, a PE ratio of -250.21, a price-to-earnings-growth ratio of 1.94 and a beta of 1.29. The firm’s fifty day moving average is $56.66 and its two-hundred day moving average is $46.34. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67.

Bruker (NASDAQ:BRKR) last issued its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The business had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd were issued a $0.05 dividend. The ex-dividend date was Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s dividend payout ratio is presently -83.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.